Welcome to Hangzhou Evershine Pharmaceutical Technology Co.,ltd. website!
中文版
|
English
Home
About us
Products
News
Jobs
Order
Contact us
Home
About us
Products
News
Company News
Industry News
Jobs
Order
Contact us
中文
EN
NEWS
Company News
Industry News
Industry News
Position:Home > News > Industry News
Sanofi's SGLT-1/2 dual-effect inhibitor sotagliflozin (sogliflozin) was approved by the European Union
2019-05-24
Comparison of CLL targeted therapy drugs: Ibrutinib VS. Venetoclax
2019-05-07
AbbVie's Venetoclax receives FDA Breakthrough Therapy designation for the 5th time
2019-04-23
Merck and Pfizer's SGLT inhibitor safety test upgraded to efficacy test drug source analysis
2016-06-15
Enpagliflozin clinically shows renal dysfunction and drug source analysis
2016-06-15
5 Records
Home
|
About us
|
Products
|
News
|
Jobs
|
Order
|
Contact us
Tel: +86-571-58120272 Mobile: +86-171-8571-4011(Manager Huang) +86-17185714471(Manager Xu) +86-130-6780-5092
E-mail:
sales@searchem.net
QQ:3506894070(Manager Huang) 2212139268(Manager Xu)
Copyright(C)2024,
Hangzhou Evershine Pharmaceutical Technology Co.,ltd.
All Rights Reserved.
Supported by
ChemNet
ChinaChemNet
Follow us
For more exciting content, please follow us